Cargando…
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial
BACKGROUND: With no approved treatments in Japan for the prevention of hereditary angioedema (HAE) attacks, there is a significant unmet need for long‐term prophylactic therapies for Japanese patients with HAE. Berotralstat (BCX7353) is an oral, once‐daily, highly selective inhibitor of plasma kalli...
Autores principales: | Ohsawa, Isao, Honda, Daisuke, Suzuki, Yusuke, Fukuda, Tomoo, Kohga, Keisuke, Morita, Eishin, Moriwaki, Shinichi, Ishikawa, Osamu, Sasaki, Yoshihiro, Tago, Masaki, Chittick, Greg, Cornpropst, Melanie, Murray, Sharon C., Dobo, Sylvia M., Nagy, Eniko, Van Dyke, Sharon, Reese, Lacy, Best, Jessica M., Iocca, Heather, Collis, Phil, Sheridan, William P., Hide, Michihiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247297/ https://www.ncbi.nlm.nih.gov/pubmed/33247955 http://dx.doi.org/10.1111/all.14670 |
Ejemplares similares
-
Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study
por: Farkas, Henriette, et al.
Publicado: (2021) -
Population pharmacokinetic modeling and simulations of berotralstat for prophylactic treatment of attacks of hereditary angioedema
por: Mathis, Amanda, et al.
Publicado: (2022) -
Prevention of Recurrent Attacks of Hereditary Angioedema (HAE): Berotralstat and Its Oral Bioavailability
por: Diaz-Menindez, Maximiliano, et al.
Publicado: (2023) -
Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema
por: Watt, Maureen, et al.
Publicado: (2023) -
Assessment of HAE prophylaxis transition from androgen therapy to berotralstat: A subset analysis of the APeX-S trial
por: Peter, Jonny G., et al.
Publicado: (2023)